Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes.

Sayyah-Melli M, Tehrani-Gadim S, Dastranj-Tabrizi A, Gatrehsamani F, Morteza G, Ouladesahebmadarek E, Farzadi L, Kazemi-Shishvan M

Saudi medical journal1 Aug 2009Cited by 14 (Europe PMC)

PMID19668882PepBankPUB-19668882

Publisher pageAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In uterine leiomyomas, lymphocyte infiltration differed significantly between Diphereline and cabergoline, but the abstract did not report the direction.
In plain wordsIn uterine leiomyomas, lymphocyte infiltration differed significantly between Diphereline and cabergoline, but the abstract did not report the direction.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedLymphocyte infiltration
Study
n = 23
Comparator
Cabergoline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg, 4 times every 28 daysAs given in this study (human).
Source sentences
Summary
There was a significant difference between the groups in the rate of lymphocyte infiltration (p=0.003), but not in other pathologic features.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirteen patients from group I, and 10 patients from group II underwent surgery.
Summary · context
60 candidates randomized to receive Diphereline 3.75 mg, 4 times every 28 days (group I), and Cabergoline 0.5 mg, once a week for 6 weeks (group II), were included in this study.
Report a problemFND-1966888201
02HumanRandomized controlled trialEfficacy outcome
In uterine leiomyomas, other pathological features did not differ significantly between Diphereline and cabergoline.
In plain wordsIn uterine leiomyomas, other pathological features did not differ significantly between Diphereline and cabergoline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOther pathological features
Study
n = 23
Comparator
Cabergoline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg, 4 times every 28 daysAs given in this study (human).
Source sentences
Summary
There was a significant difference between the groups in the rate of lymphocyte infiltration (p=0.003), but not in other pathologic features.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirteen patients from group I, and 10 patients from group II underwent surgery.
Summary · context
60 candidates randomized to receive Diphereline 3.75 mg, 4 times every 28 days (group I), and Cabergoline 0.5 mg, once a week for 6 weeks (group II), were included in this study.
Report a problemFND-1966888202
03HumanRandomized controlled trialEfficacy outcome
In surgical patients, intraoperative hemorrhage differed significantly between Diphereline and cabergoline, but the abstract did not state the direction.
In plain wordsIn surgical patients, intraoperative hemorrhage differed significantly between Diphereline and cabergoline, but the abstract did not state the direction.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedIntraoperative hemorrhage
Study
n = 23
Comparator
Cabergoline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg, 4 times every 28 daysAs given in this study (human).
Source sentences
Summary
In addition, there was a significant difference between the groups for intra-operative hemorrhage and adhesion of leiomyomas to the uterine wall.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirteen patients from group I, and 10 patients from group II underwent surgery.
Summary · context
60 candidates randomized to receive Diphereline 3.75 mg, 4 times every 28 days (group I), and Cabergoline 0.5 mg, once a week for 6 weeks (group II), were included in this study.
Report a problemFND-1966888207
04HumanRandomized controlled trialEfficacy outcome
In surgical patients, leiomyoma adhesion differed significantly between Diphereline and cabergoline, but the abstract did not state the direction.
In plain wordsIn surgical patients, leiomyoma adhesion differed significantly between Diphereline and cabergoline, but the abstract did not state the direction.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedLeiomyoma adhesion to uterine wall
Study
n = 23
Comparator
Cabergoline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg, 4 times every 28 daysAs given in this study (human).
Source sentences
Summary
In addition, there was a significant difference between the groups for intra-operative hemorrhage and adhesion of leiomyomas to the uterine wall.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirteen patients from group I, and 10 patients from group II underwent surgery.
Summary · context
60 candidates randomized to receive Diphereline 3.75 mg, 4 times every 28 days (group I), and Cabergoline 0.5 mg, once a week for 6 weeks (group II), were included in this study.
Report a problemFND-1966888208
05HumanRandomized controlled trialEfficacy outcome
In the Diphereline surgical group, leiomyoma mitotic index ranged between 0-10.
In plain wordsIn the Diphereline surgical group, leiomyoma mitotic index ranged between 0-10.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableMitotic index
Study
n = 13
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg, 4 times every 28 daysAs given in this study (human).
Measurements
Mitotic index
0 to 10 index
Both groups
Source sentences
Summary
In both groups, the mitotic index was between 0-10.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirteen patients from group I, and 10 patients from group II underwent surgery.
Summary · context
60 candidates randomized to receive Diphereline 3.75 mg, 4 times every 28 days (group I), and Cabergoline 0.5 mg, once a week for 6 weeks (group II), were included in this study.
Report a problemFND-1966888203
06HumanRandomized controlled trialEfficacy outcome
In symptomatic patients, leiomyoma number did not differ significantly between Diphereline and cabergoline.
In plain wordsIn symptomatic patients, leiomyoma number did not differ significantly between Diphereline and cabergoline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLeiomyoma number
Study
n: not reported in source
Comparator
Cabergoline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg, 4 times every 28 daysAs given in this study (human).
Source sentences
Summary
While there was no significant difference between the groups in the number (p=0.30), and volume of leiomyomas (p=0.65), however, changes in the uterine artery circulation was significant (p=0.001 [group I], p=0.026 [group II]).
1 context sentence(design, population, supporting numbers)
Summary · context
60 candidates randomized to receive Diphereline 3.75 mg, 4 times every 28 days (group I), and Cabergoline 0.5 mg, once a week for 6 weeks (group II), were included in this study.
Report a problemFND-1966888204
07HumanRandomized controlled trialEfficacy outcome
In symptomatic patients, leiomyoma volume did not differ significantly between Diphereline and cabergoline.
In plain wordsIn symptomatic patients, leiomyoma volume did not differ significantly between Diphereline and cabergoline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLeiomyoma volume
Study
n: not reported in source
Comparator
Cabergoline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg, 4 times every 28 daysAs given in this study (human).
Source sentences
Summary
While there was no significant difference between the groups in the number (p=0.30), and volume of leiomyomas (p=0.65), however, changes in the uterine artery circulation was significant (p=0.001 [group I], p=0.026 [group II]).
1 context sentence(design, population, supporting numbers)
Summary · context
60 candidates randomized to receive Diphereline 3.75 mg, 4 times every 28 days (group I), and Cabergoline 0.5 mg, once a week for 6 weeks (group II), were included in this study.
Report a problemFND-1966888205

Studies that did not test the peptide alone1

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
Uterine artery circulation changed significantly in both Diphereline and cabergoline groups, with no direction reported.
In plain wordsUterine artery circulation changed significantly in both Diphereline and cabergoline groups, with no direction reported.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedUterine artery circulation
Study
n: not reported in source
Comparator
Before treatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
While there was no significant difference between the groups in the number (p=0.30), and volume of leiomyomas (p=0.65), however, changes in the uterine artery circulation was significant (p=0.001 [group I], p=0.026 [group II]).
1 context sentence(design, population, supporting numbers)
Summary · context
60 candidates randomized to receive Diphereline 3.75 mg, 4 times every 28 days (group I), and Cabergoline 0.5 mg, once a week for 6 weeks (group II), were included in this study.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1966888206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.